Kukko V, et al. - Investigators examined 76,874 males identified from the Finnish Cancer Registry during 1996–2015 to assess the relationship between allopurinol use and incidence of prostate cancer (PCa). They did not find any variations in follow-up time (median: 17 years) and risk of PCa with allopurinol use, and they did not identify any relation between allopurinol use and the risk of high-grade or metastatic cancer. Overall, the investigators found no delayed risk associations in the lag-time analyses.